Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04104659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04104659 · ClinicalTrials.gov record · last posted 2026-06-08

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

Study acronym: MKADAD
StatusEnrolling by Invitation
PhaseNot specified
Started2021-03-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The recent development of a PET tracer,\[18F\]MK-6240(an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology. The investigators will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation. This study of tau PET using \[18F\]MK-6240 is performed in conjunction with DIAN and DIAN Extended Registry (DIAN-EXR).

Amendment record 8 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 8 times since 2019-09-23; most recent amendment 2026-06-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-01-12
Status change Recruiting→Enrolling by Invitationv6
2021-07-12
Status change Active, Not Recruiting→Recruitingv4
2020-05-28
Status change Recruiting→Active, Not Recruitingv1
Trial Details
NCT Number NCT04104659
Lead Sponsor Tammie L. S. Benzinger, MD, PhD
Conditions Alzheimer Disease
Enrollment 200 participants
Start Date 2021-03-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08